Bright Minds Biosciences Inc.(DRUG)Earnings, Financials & Key Ratios
DRUG•NASDAQ
$64.64
Price updated Jul 7, 2026
AboutBright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$14M-404.1%
- Net Income-$12M-336.5%
- EPS (Diluted)-1.78-173.8%
- ROE-27.93%+39.5%
DRUG Price & Volume
Bright Minds Biosciences Inc. (DRUG) stock price & volume — 10-year historical chart
Loading chart...
Clinical Scaling Drives Significant Capital Expenditure Inflection
Investment Thesis • Updated 2026Q2
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
Key Thesis Takeaways
- Bright Minds Biosciences has transitioned into a capital-intensive clinical-stage entity, evidenced by R&D spending surging to $13.3M in 2026Q2.
- While the company maintains a robust liquidity position with $309.3M in cash, the lack of operating leverage and widening $15.6M operating loss suggest a high-risk profile dependent on successful trial outcomes.
- Investors should monitor the sustainability of this cash runway as the firm continues to rely on equity-linked incentives, such as the $1.3M in stock-based compensation recorded in 2026Q1, to manage its operational burn.
Verdict Logic
while the $309.3M cash position provides a substantial liquidity buffer, the absence of revenue and the rapid escalation of R&D costs to $13.3M per quarter warrant a cautious, wait-and-see approach regarding clinical trial milestones.
DRUG Growth Metrics
Bright Minds Biosciences Inc. (DRUG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-699.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-336.01%
Return on Capital
10 Years-92.27%
5 Years-69.89%
3 Years-54.67%
Last Year-31.8%
DRUG Recent Earnings
Bright Minds Biosciences Inc. (DRUG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (100%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$0.80+31.6%
$1.17
Rev
—
—
Q2 2026
May 19, 2026Metric
Actual
Est
EPS
$0.80+12.7%
$0.92
Rev
—
—
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.70+28.6%
$0.98
Rev
—
—
Q4 2025
Dec 23, 2025Metric
Actual
Est
EPS
$0.41+27.1%
$0.56
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.80vs $1.17+31.6% | — |
| Q2 2026 | May 19, 2026 | $0.80vs $0.92+12.7% | — |
| Q1 2026 | Feb 12, 2026 | $0.70vs $0.98+28.6% | — |
| Q4 2025 | Dec 23, 2025 | $0.41vs $0.56+27.1% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Bright Minds Biosciences Inc. (DRUG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $64.64 | $501.7M | -51.61 | — | — | -27.93% | — | |
| $12.99 | $1.25B | -4.22 | — | — | -151.02% | — | |
| $5.19 | $1.91B | -1.78 | 1227.6% | -19019.44% | -366.21% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $4.16 | $71.91M | -3.10 | — | -1070.26% | — | — |
Compare DRUG vs Peers
Bright Minds Biosciences Inc. (DRUG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when DRUG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DRUG Frequently Asked Questions
Bright Minds Biosciences Inc. (DRUG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is DRUG profitable?
Bright Minds Biosciences Inc. (DRUG) reported a net loss of $27.5M for fiscal year 2025.
Dividend & Returns
What is DRUG's return on equity?
Bright Minds Biosciences Inc. (DRUG) has a return on equity (ROE) of -27.9%. Negative ROE indicates the company is unprofitable.
What is Bright Minds Biosciences Inc.'s free cash flow?
Bright Minds Biosciences Inc. (DRUG) had negative free cash flow of $20.1M in fiscal year 2025, likely due to heavy capital investments.